Shijiazhuang Yiling Pharmaceutical Co., Ltd.
002603
Rangering i aksjer
#4182
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and... Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Aksjekurs
$2.29
Markedsverdi
$3.83B
Endring (1 dag)
3.06%
Endring (1 år)
-6.38%
Land
CN
Handel Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Kategori
Healthcare
P/B-forhold for Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
P/B-forhold per October 2026 TTM: 2.30
Ifølge Shijiazhuang Yiling Pharmaceutical Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 2.30. Ved slutten av 2023 hadde selskapet et P/B-forhold på 3.37.
P/B-historikk for Shijiazhuang Yiling Pharmaceutical Co., Ltd. fra 2008 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 2.30 | -12.10% |
| 2024 | 2.62 | -22.28% |
| 2023 | 3.37 | -26.48% |
| 2022 | 4.58 | 26.81% |
| 2021 | 3.61 | 5.85% |
| 2020 | 3.41 | 82.65% |
| 2019 | 1.87 | 19.92% |
| 2018 | 1.56 | -36.50% |
| 2017 | 2.45 | -31.76% |
| 2016 | 3.59 | -13.52% |
| 2015 | 4.16 | 17.24% |
| 2014 | 3.54 | -17.08% |
| 2013 | 4.27 | 29.26% |
| 2012 | 3.31 | -17.86% |
| 2011 | 4.03 | -70.70% |
| 2010 | 13.74 | -26.60% |
| 2009 | 18.72 | -38.84% |
| 2008 | 30.61 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 3.8424 | 66.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 17.3539 | 653.53% |
US
|
|
| - | - |
IT
|
